Overview

To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
To investigate efficacy and safety of pemetrexed as second or third line therapy in patients with non-small cell lung cancer (NSCLC).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Pemetrexed